Search

314 results for "lecanemab".

Research summaries 285

Showing the best 200 of 285, 161–170, page 17 of 20. Filter these by subject, year and score in the research library →

1. Alzheimer’s disease basics: we all should knowResearch summary

   Research summaries · alzhub.org/study/alzheimers-disease-basics-we-all-should-know-40639927

   … cognitive impairment, while lecanemab showed 27% cognitive benefit in early AD. Aducanumab, despite initial promise, was discontinued in 2024 due to limited efficacy and safety concerns. Adverse events like amyloid-related …

2. Amyloid-Related Imaging Abnormalities (ARIA) in Anti-Amyloid Therapies for Alzheimer's Disease: An Update from the Alzheimer's Association ARIA WorkgroupResearch summary

   Research summaries · alzhub.org/study/amyloid-related-imaging-abnormalities-aria-in-anti-amyloid-therapies-912127c4

   … about 12.6%/17.3% of lecanemab patients and 24%/31% of donanemab patients; most cases are mild or symptom-free and caught on routine MRI, but in roughly 1-2% of cases ARIA has caused permanent disability or death. People with two …

3. Antiamyloid treatment for dementia: concerns outweigh hopesResearch summary

   Research summaries · alzhub.org/study/antiamyloid-treatment-for-dementia-concerns-outweigh-hopes-40511512

   … including Aducanumab Lecanemab and Donanemab, have demonstrated some benefits but the effects are small in size and may be due to bias. This review states that recent trials of antibodies including aducanumab, lecanemab and …

4. Anticuerpos monoclonales antiamiloide y enfermedad de Alzheimer: ¿estamos preparados?Research summary

   Research summaries · alzhub.org/study/anticuerpos-monoclonales-antiamiloide-y-enfermedad-de-alzheimer-d85edb6b

   ResumenLa llegada de los anticuerpos monoclonales lecanemab y donanemab marca un cambio de paradigma en el tratamiento de la enfermedad de Alzheimer, transitando del nihilismo terapéutico a la era de las terapias modificadoras de …

5. Anti‐amyloid antibodies in Europe: Where are we now?Research summary

   Research summaries · alzhub.org/study/antiamyloid-antibodies-in-europe-where-are-we-now-41810890

   … −0.45 points between lecanemab and placebo in the adjusted mean change from baseline on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) at 18 months (the primary endpoint). Safety concerns focused on amyloid-related …

6. Biogen to Realign Resources for Alzheimer's Disease Franchise (Aduhelm discontinuation)Research summary

   Research summaries · alzhub.org/study/biogen-to-realign-resources-for-alzheimer-s-disease-franchise-aduhelm-49a9a379

   … redirecting resources to lecanemab (Leqembi) and other pipeline drugs, including two tau-targeting compounds (BIIB080, BIIB113). Biogen stated the decision was not driven by new safety or efficacy concerns, but by the cost of …

7. Both Amyloid and Tau Assessments Are Desired Before Initiating Disease-modifying Therapy for Alzheimer Disease: Three Real-world CasesResearch summary

   Research summaries · alzhub.org/study/both-amyloid-and-tau-assessments-are-desired-before-initiating-40108731

   … 3 trial results,5,6 lecanemab and donanemab are currently designed to be used in patients who exhibit mild cognitive impairment or mild dementia due to AD pathology. We strongly suggest that both Aβ and tau assessments are …

8. Brain-resident myeloid cells promote rapid leukocyte adhesion in leptomeningeal vessels after anti-Aβ immunotherapyResearch summary

   Research summaries · alzhub.org/study/brain-resident-myeloid-cells-promote-rapid-leukocyte-adhesion-in-005bc584

   … including aducanumab and lecanemab, rapidly initiated microglial activation and spatial reorganization within 24 hours of dosing, with recruitment to plaque-associated regions, stabilizing plaque growth. Aducanumab and lecanemab …

9. Clinical progression on CDR‐SB©: Progression‐free time at each 0.5 unit level in dominantly inherited and sporadic Alzheimer's disease populationsResearch summary

   Research summaries · alzhub.org/study/clinical-progression-on-cdrsb-progressionfree-time-at-each-0-5-unit-40911712

   … Using PFT, continuous lecanemab treatment for 3 years is estimated to delay disease progression by 0.62 years in the sporadic population. PFT provides a benchmark for expressing clinical progression and treatment effects and can …

10. Clinical trials of new drugs for Alzheimer disease: a 2020-2023 updateResearch summary

    Research summaries · alzhub.org/study/clinical-trials-of-new-drugs-for-alzheimer-disease-a-2020-2023-update-37784171

    … approved aducanumab and lecanemab, both amyloid-targeting antibodies, ending nearly two decades without new Alzheimer drugs. It is a report on the trial landscape, not evidence that these drugs cure or prevent the disease. The …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

28781 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-06. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.